EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) enjoyed a 109.05% run-up in share price since hitting record low of $1.05. The stock managed -6.6% fall and now stands at $2.19 as of 3/22/2019. At a recent session, the prices were hovering between $2.145 and $2.36. This company shares are 189.04% off its target price of $6.33 and the current market capitalization stands at $224.11M. The recent change has given its price a -9.98% deficit over SMA 50 and -44.29% deficit over its 52-week high. The stock witnessed -17.17% declines, 4.52% gains and -12.2% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found EYPT’s volatility during a week at 6.37% and during a month it has been found around 6.04%.EyePoint Pharmaceuticals, Inc. (EYPT) Top Holders
Institutional investors currently hold around $121 million or 62% in EYPT stock. Look at its top three institutional owners: Essex Woodlands Management, Inc. owns $91.98 million in EyePoint Pharmaceuticals, Inc., which represents roughly 41.04% of the company’s market cap and approximately 76.02% of the institutional ownership. Similar statistics are true for the second largest owner, Hightower Advisors, Llc, which owns 5,260,088 shares of the stock are valued at $11.55 million. The third largest holder is Vanguard Group Inc, which currently holds $5.55 million worth of this stock and that ownership represents nearly 2.48% of its market capitalization.
At the end of December reporting period, 32 institutional holders increased their position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by some 6,308,823 shares, 13 decreased positions by 731,167 and 9 held positions by 47,961,085. That puts total institutional holdings at 55,001,075 shares, according to SEC filings. The stock grabbed 18 new institutional investments totaling 1,114,980 shares while 10 institutional investors sold out their entire positions totaling 358,186 shares.EyePoint Pharmaceuticals, Inc. (EYPT) Analyst Guide
Several analysts have released their opinion on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].